FLT3 and acute myeloid leukemia: For example, if a FLT3-ITD AML patient develops resistance to sorafenib due to the selection of a subclone harboring a FLT3-ITD-D835 mutation, or induction of this mutation during 7 + 3, the patient is still likely to be sensitive to crenolanib or lestaurtinib (Table 2).